![DARA BioSciences, Inc. Logo](/news-release/logo/217527/0/217527.jpg?lastModified=12%2F09%2F2016%2022%3A38%3A34&size=2)
DARA BioSciences Announces Launch of Bionect for Treatment of Skin Irritation and Burns Associated With Radiation Therapy for Cancer
06 juin 2012 08h45 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., June 6, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) (the "Company" or "DARA"), an emerging oncology and oncology-support specialty pharmaceutical company, announced...
![DARA BioSciences, Inc. Logo](/news-release/logo/217527/0/217527.jpg?lastModified=12%2F09%2F2016%2022%3A38%3A34&size=2)
DARA BioSciences Announces New Organizational Responsibilities in Preparation for the Launch of New Products and to Strengthen Product Development Capabilities
29 mai 2012 08h45 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., May 29, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) (the "Company" or "DARA"), an emerging oncology and oncology-support specialty pharmaceutical company, today...
![DARA BioSciences, Inc. Logo](/news-release/logo/217527/0/217527.jpg?lastModified=12%2F09%2F2016%2022%3A38%3A34&size=2)
DARA BioSciences Reports Financial Results for the First Quarter 2012 and Provides Key Highlights of the Company's Business Milestones
21 mai 2012 11h04 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., May 21, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) (the "Company" or "DARA") today announced the financial results for the period ending March 31, 2012. The Company...
![DARA BioSciences, Inc. Logo](/news-release/logo/217527/0/217527.jpg?lastModified=12%2F09%2F2016%2022%3A38%3A34&size=2)
DARA BioSciences Announces New Analysis of Patient Self-Reported Diary Results in a Phase 2a Clinical Trial of KRN5500 in Patients With Cancer and Neuropathic Pain
09 mai 2012 08h45 HE
|
DARA BioSciences, Inc.
External Data Analysis Confirms Earlier Published Drug Efficacy Signal in Patients With Treatment-Refractory Neuropathic Pain
DARA to Continue Phase 2 Development Program After Formulation...
![DARA BioSciences, Inc. Logo](/news-release/logo/217527/0/217527.jpg?lastModified=12%2F09%2F2016%2022%3A38%3A34&size=2)
DARA BioSciences Closes $10.25 Million Public Offering and Regains Compliance With NASDAQ's Stockholders' Equity Requirement
01 mai 2012 08h45 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., May 1, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) (the "Company" or "DARA") announced that at a closing completed on April 26, 2012, it received $10,250,000 in gross...
![DARA BioSciences, Inc. Logo](/news-release/logo/217527/0/217527.jpg?lastModified=12%2F09%2F2016%2022%3A38%3A34&size=2)
DARA BioSciences to Raise $10.1 Million in Public Offering
09 avr. 2012 09h05 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., April 9, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) (the "Company" or "DARA") announced that it entered into definitive securities purchase agreements with certain...
![DARA BioSciences, Inc. Logo](/news-release/logo/217527/0/217527.jpg?lastModified=12%2F09%2F2016%2022%3A38%3A34&size=2)
DARA BioSciences Obtains U.S. Rights to Co-Promote Bionect(R), an FDA Approved Topical Hyaluronic Acid, Exclusively in the Radiation and Oncology Markets
26 mars 2012 08h45 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., March 26, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced today that it entered into an exclusive agreement with Innocutis Holdings, LLC ("Innocutis") for U.S....
![DARA BioSciences, Inc. Logo](/news-release/logo/217527/0/217527.jpg?lastModified=12%2F09%2F2016%2022%3A38%3A34&size=2)
DARA BioSciences Signs Exclusive Agreement With Uman Pharma for U.S. Commercialization Rights to Gemcitabine
15 févr. 2012 08h30 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., Feb. 15, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced today that it entered into an exclusive U.S. agreement with Uman Pharma Inc. for commercial rights to...
![DARA BioSciences, Inc. Logo](/news-release/logo/217527/0/217527.jpg?lastModified=12%2F09%2F2016%2022%3A38%3A34&size=2)
DARA BioSciences Signs Definitive Agreement to Raise $1.7 Million in Registered Direct Offering
18 janv. 2012 08h45 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., Jan. 18, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) today announced that it has entered into a definitive agreement with one institutional investor providing for the...
![DARA BioSciences, Inc. Logo](/news-release/logo/217527/0/217527.jpg?lastModified=12%2F09%2F2016%2022%3A38%3A34&size=2)
DARA BioSciences Announces Acquisition of U.S. Marketing Rights to Soltamox(TM), an FDA Approved Liquid Formulation of Tamoxifen for the Treatment of Breast Cancer
17 janv. 2012 08h45 HE
|
DARA BioSciences, Inc.
Soltamox™ and Other Product Opportunities Enabled Through Acquisition of Oncogenerix, a Private South Carolina-Based Oncology Company
Additional Opportunities to Develop and Distribute...